Lysophosphatidic acid in ovarian cancer patients;Lysofosfatidová kyselina u pacientek s karcinomem ovaria

Ceska Gynekologie

Volumn 71, Issue 4, 2006, Pages 312-317

  Sedláková, Iva ^a   Vavrova J ^b   Tosner J ^a   Hanousek, L ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c Pardubice Regional Hospital   (Czech Republic)

Author keywords

Lysophosphatidic acid; Marker; Ovarian cancer

Indexed keywords

LYSOPHOSPHATIDIC ACID;

ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; ULTRAVIOLET RADIATION; VENOUS BLOOD;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33747428361     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Baker, D.L., Morrison, P., Miller, B., et al. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA, 287, 2002, p. 3081-3082.
2. Barakat, R.R., Bevers, M.W., Gershenson, M.D., Hoskins, W.J. Handbook of gynecologic oncology - second edition. London, Martin Dunitz Publishers, 2002, p. 254-255.
3. Bouda, J., Bouda, J., jr. Gynekologické zhoubné novotvary v České republice v letech 1986-1995. Čes. Gynek., 2000, 1, s. 58-62.
4. Chen, J., et al. Production and application of LPA polyclonal antibody. Bioorganic and medical chemistry Letters, 2000, 10, p. 1691-1693.
5. Chen, Y.L., Xu, Y. Determination of lysophosphatidic acids by capillary electrophoresis with indirect ultraviolet detection. J. Chromatography, 2001, 753, p. 355-363.
6. Citterbart, K., et al. Gynekologie. Praha: Galén, 2001, s. 170-173.
7. Eder, A.M., Sasagawa, T., Mao, M., et al. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin. Cancer Res., 2000, 6, p. 2482-2491.
8. Erickson, R.J., et al. Lysophosphatidic acid and ovarian cancer: a paradigm for tumorogenesis and patients management. Prostaglandins and other lipid mediators, 2001, p. 63-81.
9. Fang, X., Schummer, M., Mao, M., et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochem. Biophys. Acta, 2002, p. 123-136.
10. Fishman, D., Rourke, J., Karnik, N., et al. Povedou nové metodiky ke změnám v časné detekci ovariálního karcinomu? Gynek. po promoci, 2003, 5, s. 48-53.
11. Flordelis, CH.S., Berguerand, M., Gouache, P., et al. Elevated blood levels of lipid might be earlier marker of ovarian cancer. Clin. Lab. Letters, 2000, 19, s. 147-148.
12. Goetzl, E.J., Dolezalova, H., Kong, Y., et al. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res., 1999, 59, p. 5370-5375.
13. Hu, Y.L., Tee, M.K., Goetzl, E.J., et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl. Cancer Inst., 2001, 93, p. 762-768.
14. Meng, Y., Kang, S., So, J., et al. Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis. Gynec. Oncol., 2005, 96, p. 462-469.
15. Ramachandran, S., et al. Lysophosphatidic acid induces glycodelin gene expression in cancer cells. Cancer Letters, 2002, 177, p. 197-202.
16. Rob, L. Ovariální karcinom - chemosenzitivní, špatně kurabilní - možnosti zlepšeni stavu. 3. Bauerovy dny, Praha, 1999
17. Robová, H., Rob, L., Pluta, J., Kačírek, J. Zhoubné nádory ovaria. Moderní gynekologie a porodnictví - reprint, 2000, 4, s. 679-693.
18. Sedláková, I. Faktory ovlivňující výskyt a úspěšnost léčby gynekologických nádorů - ovariálních karcinomů. Disertačni práce. 2003, s. 74.
19. So, J., Navari, J., Wang, F.O., et al. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynec. Oncol., 2004, 95, p. 314-322.
20. So, J., Wang, F., Navari, J., et al. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynec. Oncol., 2005, 97, p. 870-878.
21. Sutphen, R., Xu, Y., Wilbanks, D., et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidem., 2004, 13, p. 1185-1191.
22. Swarthout, J.T., Walling, H.W. Lysophosphatidic acid: receptors, signaling and survival. Cellular and Molecular Life Sciences, 2000, 57, p. 1978-1985.
23. Tanyi, L. J., Morris, A. J., Wolf, J. K., et al. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res., 2003, 63, p. 1073-1082.
24. Tesařík, Z. K problematice etiologie a vyšetř ování ovariálního karcinomu. Základní principy léčby karcinomu ovaria. Chemoterapie v léčbě karcinomu ovaria. Prakt. Gynek., 1997, 3, s. 24-25.
25. Xu, Y., Shen, Z., Wiper, D.W., et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998, 280: p. 719-723.